TABLE 3.
Comparison of neutralization and HI antibody titers for a subset of serum samples
| Serum sample | Neutralization titer |
HI titer |
||||
|---|---|---|---|---|---|---|
| B/Florida/04/06 (B/Yamagata) | B/Brisbane/60/08 (B/Victoria) | B/Georgia/07/10 (B/Victoria) | B/Georgia/07/10 (B/Victoria) | B/Florida/04/06 (B/Yamagata) | B/Brisbane/60/08 (B/Victoria) | |
| Gnotobiotic piglet serum | ≤5 | ≤5 | ≤5 | ≤5 | ≤5 | ≤5 |
| S1 (11-A) | ≤5 | ≥1,280 | 640 | 320 | ≤5 | 320 |
| S2 (11-A) | ≤5 | ≤5 | ≤5 | ≤5 | ≤5 | ≤5 |
| S3 (11-A) | ≤5 | ≤5 | ≤5 | ≤5 | ≤5 | ≤5 |
| S4 (11-A) | ≤5 | ≤5 | ≤5 | ≤5 | ≤5 | ≤5 |
| S5 (11-A) | ≤5 | ≥1,280 | ≥1,280 | 320 | ≤5 | 640 |
| S6 (11-A) | ≤5 | ≥1,280 | ≥1,280 | 320 | ≤5 | 640 |
| S7 (11-A) | ≤5 | ≤5 | ≤5 | ≤5 | ≤5 | ≤10 |
| S8 (11-A) | ≤5 | ≥1,280 | ≥1,280 | 320 | ≤5 | 640 |
| S9 (11-A) | ≤5 | ≤5 | ≤5 | ≤5 | ≤5 | ≤5 |
| S10 (11-A) | ≤5 | ≤5 | ≤5 | ≤5 | ≤5 | ≤5 |
| S11(11-A) | ≤5 | ≤5 | ≤5 | ≤5 | ≤5 | ≤5 |
| S12 (11-A) | ≤5 | ≤5 | ≤5 | ≤5 | ≤5 | ≤5 |
| S13 (11-B) | ≤5 | ≤5 | ≤5 | ≤5 | ≤5 | ≤5 |
| S14 (11-B) | ≤5 | ≥1,280 | 640 | 320 | ≤5 | 1,280 |
| S15 (11-B) | ≤5 | ≥1,280 | ≥1,280 | 320 | ≤5 | 640 |
| S16 (11-C) | ≤5 | ≤5 | ≤5 | ≤5 | ≤5 | ≤5 |
| S17 (11-C) | ≤5 | ≤5 | ≤5 | ≤5 | ≤5 | ≤5 |
| S18 (11-C) | ≤5 | ≤5 | ≤5 | ≤5 | ≤5 | ≤5 |
| S19 (11-C) | ≤5 | ≥1,280 | ≥1,280 | 320 | ≤5 | 640 |
| S20 (11-D) | ≤5 | ≥1,280 | ≥1,280 | 320 | ≤5 | 1,280 |